Business Context and Reporting Period
Company: Radiopharm Theranostics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of January 2026 (covering activities through January 28, 2026)
Context: The filing serves as a conduit for a Public Notice released to the Australian Securities Exchange titled "Quarterly Activities/Appendix 4C Cash Flow Report."
Key Financial Metrics
The provided Form 6-K text acts as a cover document and does not contain specific financial data points. The actual financial details are located in the attached Exhibit 99.1 ("Quarterly Activities/Appendix 4C Cash Flow Report").
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Referenced in the title of the attached exhibit, but specific values are not present in the text.
- Debt and Liquidity: Not provided in the filing text.
- Margins: Not provided in the filing text.
Material Changes
The filing text does not disclose specific material changes versus prior periods. It only confirms the publication of a quarterly update and cash flow report.
Guidance, Outlook, and Risks
Management Commentary: The filing includes an explanatory note confirming the release of the quarterly activities report but contains no narrative commentary, outlook, or guidance within the text provided.
Risks and Contingencies: No specific risks or contingencies are detailed in the Form 6-K cover text.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Quarterly Activities/Appendix 4C Cash Flow Report) for actual cash balance, burn rate, and revenue figures, as these are absent from the cover letter.
- Verify the specific operational milestones achieved during the quarter as detailed in the attached Public Notice.
- Confirm the company's current cash runway based on the Appendix 4C data to assess liquidity status.
- Check for any updates on clinical trial progress or regulatory approvals mentioned in the full quarterly activities report.